Literature DB >> 27549096

Poorly controlled gout: who is doing poorly?

Faith Li-Ann Chia.   

Abstract

Gout, an inflammatory arthritis caused by the deposition of monosodium urate crystals, is commonly seen in primary care and specialist clinics. In recent years, there has been a resurgence of interest in gout due to advances in therapies and the understanding of pathophysiology, with new guidelines being published by international bodies. However, there is still a gap between the goals of treatment and actual day-to-day practice. Barriers that result in poorly controlled gout include patient factors such as lack of understanding of the disease, stigma and nonadherence to treatment, as well as physician factors such as knowledge gaps, inadequate use of allopurinol and lack of ownership of the disease. The medical profession needs to do more to bridge the gap through physician and patient education, identification of treatment targets with appropriate use of drugs, and dissemination of guidelines. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  allopurinol; drug hypersensitivity; hyperuricaemia; medication adherence

Mesh:

Substances:

Year:  2016        PMID: 27549096      PMCID: PMC4993963          DOI: 10.11622/smedj.2016129

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  31 in total

1.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

Authors:  Kelsey M Jordan; J Stewart Cameron; Michael Snaith; Weiya Zhang; Michael Doherty; Jonathan Seckl; Aroon Hingorani; Richard Jaques; George Nuki
Journal:  Rheumatology (Oxford)       Date:  2007-05-23       Impact factor: 7.580

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  Treat to target in gout by combining two modes of action.

Authors:  Tim L Jansen
Journal:  Rheumatology (Oxford)       Date:  2014-04-23       Impact factor: 7.580

4.  Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system.

Authors:  Bernard Yu-Hor Thong; Khai-Pang Leong; Chwee-Ying Tang; Hiok-Hee Chng
Journal:  Ann Allergy Asthma Immunol       Date:  2003-03       Impact factor: 6.347

5.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

6.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Authors:  Fernando Perez-Ruiz; Marcelo Calabozo; Jose I Pijoan; Ana M Herrero-Beites; Ana Ruibal
Journal:  Arthritis Rheum       Date:  2002-08

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

8.  Desensitization to allopurinol in patients with gout and cutaneous reactions.

Authors:  A G Fam; J Lewtas; J Stein; T W Paton
Journal:  Am J Med       Date:  1992-09       Impact factor: 4.965

9.  Adherence with urate-lowering therapies for the treatment of gout.

Authors:  Leslie R Harrold; Susan E Andrade; Becky A Briesacher; Marsha A Raebel; Hassan Fouayzi; Robert A Yood; Ira S Ockene
Journal:  Arthritis Res Ther       Date:  2009-03-27       Impact factor: 5.156

10.  Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice.

Authors:  Elizabeth Cottrell; Valerie Crabtree; John J Edwards; Edward Roddy
Journal:  BMC Fam Pract       Date:  2013-11-14       Impact factor: 2.497

View more
  4 in total

1.  Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.

Authors:  Lydia Wenxin Lin; Gim Gee Teng; Anita Yee Nah Lim; Joanne Su-Yin Yoong; Niklas Zethraeus; Hwee-Lin Wee
Journal:  Int J Rheum Dis       Date:  2018-12-16       Impact factor: 2.454

2.  How Are We Managing Patients with Hyperuricemia and Gout: A Cross Sectional Study Assessing Knowledge and Attitudes of Primary Care Physicians?

Authors:  Sanja Zuzic Furlan; Doris Rusic; Josko Bozic; Mirjana Rumboldt; Zvonko Rumboldt; Marko Rada; Marion Tomicic
Journal:  Int J Environ Res Public Health       Date:  2021-01-30       Impact factor: 3.390

Review 3.  Improving adherence to gout therapy: an expert review.

Authors:  Fernando Perez-Ruiz; Giovambattista Desideri
Journal:  Ther Clin Risk Manag       Date:  2018-05-03       Impact factor: 2.423

4.  A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.

Authors:  C A Janssen; M A H Oude Voshaar; H E Vonkeman; M Krol; M A F J van de Laar
Journal:  Clin Rheumatol       Date:  2018-05-02       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.